LOCALLY ADVANCED/METASTATIC SOLID TUMORS
Clinical trials for LOCALLY ADVANCED/METASTATIC SOLID TUMORS explained in plain language.
Never miss a new study
Get alerted when new LOCALLY ADVANCED/METASTATIC SOLID TUMORS trials appear
Sign up with your email to follow new studies for LOCALLY ADVANCED/METASTATIC SOLID TUMORS, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug targets Hard-to-Treat cancers in early trial
Disease control Recruiting nowThis study tests a new experimental drug called ISM3412 in about 80 adults with advanced solid tumors that have a specific genetic change (MTAP deletion) and have stopped responding to standard treatments. The main goals are to check the drug's safety and find the best dose. The …
Matched conditions: LOCALLY ADVANCED/METASTATIC SOLID TUMORS
Phase: PHASE1 • Sponsor: InSilico Medicine Hong Kong Limited • Aim: Disease control
Last updated May 17, 2026 11:46 UTC
-
New drug ESG406 enters human trials for Hard-to-Treat cancers
Disease control Recruiting nowThis early-phase study tests a new drug called ESG406 in adults (ages 18-80) with advanced or metastatic solid tumors that have not responded to standard treatments. The main goals are to check the drug's safety and find the best dose. Researchers will also watch for any tumor sh…
Matched conditions: LOCALLY ADVANCED/METASTATIC SOLID TUMORS
Phase: PHASE1 • Sponsor: Shanghai Escugen Biotechnology Co., Ltd • Aim: Disease control
Last updated May 17, 2026 11:38 UTC
-
New drug CR-001 enters human trials for Hard-to-Treat cancers
Disease control Recruiting nowThis study tests a new drug, CR-001, in adults with advanced solid tumors that have spread. The main goal is to find a safe dose and check for side effects. About 290 people will take part in this early-phase trial.
Matched conditions: LOCALLY ADVANCED/METASTATIC SOLID TUMORS
Phase: PHASE1, PHASE2 • Sponsor: Crescent Biopharma, Inc. • Aim: Disease control
Last updated May 13, 2026 15:59 UTC